⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Pegloticase

پگلوتیکاز

⚠ Unverified

🦴 Musculo-Skeletal SystemPEGylated uricase

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Safety not established 👴 Older adults:No specific problem stated 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (BLA) BLA125293 ATC M04AX02

Market / country: 🇺🇸 USA

Krystexxa (US)

🧮 Dose calculator

Disease / regimen

Gout · Regimen source: FDA Krystexxa · 2.2

• Methotrexate and folic acid at least 4 weeks before. Stop oral urate-lowering drugs. Premedicate with antihistamine and corticosteroid. Check uric acid before each infusion (two consecutive >6 mg/dL: stop). FDA Krystexxa · 2.2 FDA Krystexxa · 2 FDA Krystexxa · Boxed Warning

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ G6PD deficiency; prior serious hypersensitivity to pegloticase. FDA Krystexxa · 4

Warnings

• Boxed warning: anaphylaxis and infusion reactions (healthcare setting only); haemolysis and methaemoglobinaemia in G6PD deficiency — screen for G6PD first. FDA Krystexxa · Boxed Warning
• Gout flares at initiation; congestive heart failure. FDA Krystexxa · 5

Formulations

8 mg/mL vial (to be diluted) — injection 🇺🇸 USA FDA Krystexxa · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Krystexxa · 8.1
“Risk Summary There are no adequate and well-controlled studies of KRYSTEXXA in pregnant women.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Krystexxa · 8.2
“Therefore, KRYSTEXXA should not be used when breastfeeding unless the clear benefit to the mother can overcome the unknown risk to the newborn/infant.”
👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Krystexxa · 8.4
“The safety and effectiveness of KRYSTEXXA in pediatric patients less than 18 years of age have not been established.”
👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Krystexxa · 8.5
“No dose adjustment is needed for patients 65 years of age and older.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)BLA125293
DailyMed (FDA label)FDA Krystexxa
MedlinePlus (NIH)Pegloticase Injection
WHO ATC/DDDM04AX02
Darooyab (Iran)Pegloticase

🇮🇷 Not found in Iran list Darooyab · G-4694/Pegloticase

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Krystexxa · 3 FDA Krystexxa · 2.2 FDA Krystexxa · 2 FDA Krystexxa · Boxed Warning FDA Krystexxa · 4 FDA Krystexxa · 5 FDA Krystexxa · 8.1 FDA Krystexxa · 8.2 FDA Krystexxa · 8.4 FDA Krystexxa · 8.5 FDA Krystexxa · SPL approval / marketing category
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-4694/Pegloticase
Clinical review⚠ Unverified

🔗 Similar drugs

For the same diseases

Allopurinol Colchicine Etoricoxib Febuxostat Indomethacin Naproxen Probenecid